SFI
CSTL icon

Susquehanna Fundamental Investments’s Castle Biosciences CSTL Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,547
Closed -$201K – 980
2022
Q4 		$201K Buy
+8,547
New +$198K ﹤0.01% 1067
2022
Q1 		$477K Sell
10,625
-2,100
-17% -$86.8K 0.01% 1095
2021
Q4 		$546K Sell
12,725
-5,255
-29% -$275K 0.01% 882
2021
Q3 		$1.2M Buy
+17,980
New +$1.27M 0.02% 793

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Susquehanna Fundamental Investments's CSTL Position: Q1 2023 in Review

Susquehanna Fundamental Investments sold out of Castle Biosciences (CSTL) in Q1 2023, closing a stake of 8,547 shares — an estimated $201K sold.

Susquehanna Fundamental Investments first reported a position in CSTL in Q3 2021 and held it in 4 quarters. The position peaked at $1.2M in Q3 2021. 148 funds tracked by Wall St. Rank hold CSTL as of Q1 2023.

  • Susquehanna Fundamental Investments reported no remaining Castle Biosciences position as of Q1 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 8,547 Castle Biosciences shares in Q1 2023, an estimated $201K.
  • Susquehanna Fundamental Investments first reported a position in Castle Biosciences in Q3 2021 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Castle Biosciences position peaked at $1.2M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2023, filed 16 May 2023.